10-QPeriod: Q1 FY2021

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2021

Filed May 4, 2021For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported robust financial results for the first quarter ended March 31, 2021. Total revenue surged by 24.2% year-over-year to $777.7 million, driven by strong performance across its key segments, particularly the Companion Animal Group (CAG). Organic revenue growth was a healthy 21.0%, underscoring the company's operational strength. The company demonstrated significant improvement in profitability, with income from operations increasing by 71.6% to $247.6 million. This was supported by a substantial expansion in gross profit margin, which rose by 310 basis points to 60.5%, attributed to higher sales volumes, pricing benefits, and operational leverage. Diluted earnings per share (EPS) also saw a significant jump to $2.35, up from $1.29 in the prior year's quarter. IDEXX maintained a strong liquidity position with $351.2 million in cash and cash equivalents and an available credit facility of $998.6 million. The company continued its share repurchase program, returning value to shareholders. The results reflect sustained demand for IDEXX's veterinary diagnostic products and services, bolstered by increased veterinary practice visits and a focus on expanded healthcare services for companion animals.

Financial Highlights

54 data points
Beta

Revenue

$777.71M

60.5% Gross Margin

Net Income

$204.29M

26.3% Net Margin

EPS (Diluted)

$2.35

Total Assets

$2.33B

Cash & Equivalents

$351.16M

Free Cash Flow

$104.26M

Financial Statements
Beta
Revenue$777.71M
Cost of Revenue$306.93M
Gross Profit$470.78M
R&D Expenses$37.58M
Operating Income$247.62M
Interest Expense$7.58M
Net Income$204.29M
EPS (Basic)$2.39
EPS (Diluted)$2.35
Shares Outstanding (Basic)85.53M
Shares Outstanding (Diluted)86.92M

Key Highlights

  • 1Total revenue increased by 24.2% to $777.7 million in Q1 2021 compared to Q1 2020.
  • 2Organic revenue growth was strong at 21.0%, indicating robust underlying business performance.
  • 3Income from operations more than doubled, increasing by 71.6% to $247.6 million.
  • 4Gross profit margin improved significantly, expanding by 310 basis points to 60.5%.
  • 5Diluted Earnings Per Share (EPS) grew substantially to $2.35 from $1.29 in the prior year.
  • 6The Companion Animal Group (CAG) segment showed impressive revenue growth of 25.5%, driven by diagnostics and consumables.
  • 7The company maintained a strong liquidity position with $351.2 million in cash and cash equivalents and ample credit facility availability.

Frequently Asked Questions

The primary driver of IDEXX's revenue growth was the strong performance in its Companion Animal Group (CAG) segment, which experienced a 25.5% increase in revenue. This growth was fueled by increased demand for companion animal diagnostics, higher clinical visits, and expanded healthcare services for pets.

IDEXX saw a significant improvement in profitability. Income from operations increased by 71.6% to $247.6 million, and the gross profit margin expanded by 310 basis points to 60.5%. This was supported by higher sales volumes, pricing benefits, and operational leverage.

IDEXX maintained a strong liquidity position with $351.2 million in cash and cash equivalents as of March 31, 2021. The company also had $998.6 million in available borrowing capacity under its credit facility. IDEXX expects these resources, combined with cash generated from operations, to be sufficient to fund its operations, capital expenditures, and anticipated growth needs for the next twelve months and the foreseeable future.

Yes, IDEXX continued its share repurchase program during the first quarter of 2021, repurchasing shares in the open market. This is viewed as a favorable means of returning value to shareholders and offsetting the dilutive effect of share-based compensation programs.